Navigation Links
LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
Date:2/1/2010

BALLERUP, Denmark, Feb. 1 /PRNewswire-USNewswire/ -- LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.  Findings from the REGION Ib study in body AK support results from the earlier REGION-I trial, a study evaluating PEP005 for the treatment of AK on the head reported in December 2009.

AK is a pre-cancerous skin condition that if left untreated, can lead to the development of skin cancer.

"PEP005 is a recent addition to LEO Pharma's robust dermatology pipeline.  We could not be happier with the preliminary findings that suggest PEP005 may be a promising new treatment option for patients with this type condition, a pre-cursor to skin cancer," said Lars Olsen, Executive Vice President for Research & Development, LEO Pharma.  

Cryotherapy, a procedure in which the surface skin lesions are frozen, is currently the most common treatment alternative for AK. It is used as the sole approach in approximately 75% of treatments for AK lesions, and in combination with topical drugs in approximately 9% of treatments. The American Academy of Dermatology reports that 40 percent of cases of squamous cell carcinoma begin as AKs.

Approximately 250 patients were enrolled in the REGION Ib study, which evaluated the use of a 0.05% concentration of PEP005 Gel applied daily as monotherapy for two consecutive days to AK lesions on non-head locations.  

PEP005 Gel demonstrated a favorable safety profile and was well tolerated; side effects were consistent with those seen in Phase II studies. There were no drug-related serious adverse events reported. The trials were initiated and run by Peplin, Inc., acquired by LEO Pharma in September 2009.  

Results from REGION I and Ib will be presented at an upcoming meeting of the American Academy of Dermatology.

LEO Pharma expects to file for regulatory approval of the treatment in the U.S. and Europe in 2011.

About Actinic Keratosis

Actinic keratosis (AK) is a common pre-cancerous skin condition caused by sun exposure, which can develop into skin cancers if left untreated. The number of AK patients is both large and rapidly growing, and AK is a serious health problem.

About LEO Pharma

Founded more than 100 years ago, LEO Pharma is an independent, research-based specialty pharmaceutical company committed to the discovery and development of novel drugs for patients within the areas of Dermatology and Critical Care Medicine. Wholly owned by The LEO Foundation, the company is headquartered in Ballerup, Denmark, outside of Copenhagen, and is represented in more than 90 countries worldwide.  Employees number more than 3,000, with 550 scientists and specialists working to develop new chemical entities.

With a strong portfolio of approved products and a robust pipeline of treatments in development for conditions including psoriasis, eczema and actinic (solar) keratosis, LEO Pharma is one of the leading dermatology companies in the U.S. and the world.  

For more information about LEO Pharma, visit www.leopharma.com.

SOURCE LEO Pharma

RELATED LINKS
http://www.leopharma.com

'/>"/>

SOURCE LEO Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
6. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
7. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
8. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... is estimated to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% ... the highest revenue, and is projected to dominate the market during the study period. ... ... Market Research Logo ...
(Date:3/24/2017)... 24, 2017  Zymo Research Corp., also ... Robotics, Inc., who designs, manufactures and distributes ... that teams Zymo Research,s DNA methylation detection ... extraction products with Hamilton,s high-throughput automation platforms. ... for microbiomics and RNA isolation for use ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental ... ... markets for Dental Implants in US$ Million. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards ... full spectrum of disordered eating, announced today that the 2017 Symposium set a new ... and several countries converged on the Green Valley Resort in Las Vegas. , ...
(Date:3/24/2017)... Northridge, CA (PRWEB) , ... March 24, 2017 ... ... Dr. Ramin Assili, announce that they are now offering treatments for sleep apnea ... treated at dental offices. Sleep apnea , specifically the obstructive type, is ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower ... upgrading their training and leads programs. , In February, 2017, Empower Brokerage introduced ... agents, Performance Partners is designed to teach how to maximize their sales efforts, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
(Date:3/23/2017)... Virginia (PRWEB) , ... March 23, 2017 , ... ... public health services to their communities, 16 more public health departments have been ... week’s decisions bring another 4.5 million people into the expanding network of communities ...
Breaking Medicine News(10 mins):